Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 67.9% in July

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 291,500 shares, a growth of 67.9% from the June 30th total of 173,600 shares. Based on an average trading volume of 72,000 shares, the days-to-cover ratio is currently 4.0 days. Currently, 1.9% of the shares of the stock are short sold.

Gyre Therapeutics Stock Performance

Shares of NASDAQ GYRE traded up $0.04 during midday trading on Friday, reaching $15.02. 32,302 shares of the stock were exchanged, compared to its average volume of 77,179. Gyre Therapeutics has a 52-week low of $4.80 and a 52-week high of $30.40. The stock has a 50 day moving average price of $12.15 and a 200-day moving average price of $15.31.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The firm had revenue of $27.17 million for the quarter. On average, equities analysts anticipate that Gyre Therapeutics will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total transaction of $282,600.00. Following the completion of the transaction, the director now directly owns 1,636 shares in the company, valued at approximately $23,116.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gyre Therapeutics

An institutional investor recently bought a new position in Gyre Therapeutics stock. Bank of New York Mellon Corp bought a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 18,266 shares of the company’s stock, valued at approximately $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.